Search
ECT-001 expanded cord blood
go.drugbank.com/drugs/DB21745InvestigationalECT-001 expanded cord blood is umbilical cord blood (UCB) that has been co-cultured and expanded with the small molecule agonist [UM-171]. … [L52013] It is being investigated in hematopoietic cell transplantation as ECT-001 expanded cord blood can demonstrate enhanced stem cell proliferation and engraftment compared to untreated UBCs.
BF-1
go.drugbank.com/drugs/DB06029ExperimentalBF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.
Linsitinib
go.drugbank.com/drugs/DB06075InvestigationalAn orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. … IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
NV1020
go.drugbank.com/drugs/DB04969InvestigationalNV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Calusterone
go.drugbank.com/drugs/DB01564ExperimentalIllicitA 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.
BGB-DXP593
go.drugbank.com/drugs/DB16357InvestigationalWith Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)) by BeiGene. … [L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants
Nicotinamide adenine dinucleotide phosphate
go.drugbank.com/drugs/DB03461ExperimentalA coenzyme composed of ribosylnicotinamide 5'-phosphate (NMN) coupled by pyrophosphate linkage to the 5'-phosphate adenosine 2',5'-bisphosphate.
AZD2389
go.drugbank.com/drugs/DB22104InvestigationalNCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).
Anatibant
go.drugbank.com/drugs/DB05038ExperimentalAnatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).
Categories: Bradykinin Receptor AntagonistsBHV-1310
go.drugbank.com/drugs/DB22674ExperimentalBHV-1310 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.